Our proprietary technology platform is based on synthetic polymer antibiotics and their unique mechanism of action which underpins our compounds.
Each product candidate has distinct characteristics, therapeutic indications, commercialisation potential and unique licensing and partnering opportunities.
Our intellectual property estate includes three patent families, including 15 patents or patent applications, which we believe provide a substantial competitive advantage for the commercial development of our technology in the major medical markets including the United States, Europe and Japan.
Our patent families cover composition of matter, application along with the unique manufacturing process we have developed.
Manufacturing scale-up is a major focus of the business and will allow us to meet anticipated clinical and early commercial demands while also reducing costs for supply.
By controlling our manufacturing processes and activities we are able to ensure consistency and meet the quality standards set by international regulatory agencies.